ReviewTranslational andrology and urology2016
Testosterone therapy in the new era of Food and Drug Administration oversight.
Review in Translational andrology and urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men.EBioMedicine · 2026Article
- Testosterone propionate andInternational journal of reproductive biomedicine · 2023Article
- Testosterone Therapy in Men with Klinefelter Syndrome: Analysis of a Global Federated Research Network.Androgens: clinical research and therapeutics · 2022Article
- Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014.The Journal of urology · 2020Article
- Androgen Effects on the Adrenergic System of the Vascular, Airway, and Cardiac Myocytes and Their Relevance in Pathological Processes.International journal of endocrinology · 2020Review
- Testosterone Management in Aging Males: Surveying Clinical Practices of Urologists and Endocrinologists in Israel.Sexual medicine · 2019Article
- Understanding the Context of High- and Low-Testosterone Prescribing Facilities in the Veterans Health Administration (VHA): a Qualitative Study.Journal of general internal medicine · 2019Article
- Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Article
- Evolution of Guidelines for Testosterone Replacement Therapy.Journal of clinical medicine · 2019Article
- Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Article
- Testosterone therapy improves erectile function and libido in hypogonadal men.Current opinion in urology · 2017Review
- Effects of Testosterone on Benign and Malignant Conditions of the Prostate.Current sexual health reports · 2017Article
- Testosterone therapy and prostate cancer.Translational andrology and urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The Food and Drug Administration (FDA) introduced changes in labeling and indications for use to testosterone products in 2015 due to a possible increased risk of cardiovascular (CV) events. This decision was made based on six clinical studies-some that supported an increased CV risk, and some that did not. Since this decision, additional studies have been published examining the interplay between hypogonadism, CV risk, and testosterone, demonstrating that the risk may be lower than originally estimated. Clinicians are placed in a difficult position, as studies support an increased mortality risk in hypogonadal men, but also an increased risk of CV events in men on testosterone therapy. As a result, many clinicians will be more selective in their prescribing of testosterone. In this review, we examine how these new guidelines arose and how they may affect prescribing habits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.